ORIGINAL RESEARCH PAPER
Volume - 13 | Issue - 12 | December - 2024 | PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH

STENOTROPHOMONAS MALTOPHILIA: AN IN-DEPTH ANALYSIS.

Anaesthesiology

Dr. Surinder Singh Sodhi* Consultant, Deptt. Of Critical Care, Grecian Super Speciality Hospital, Sector -69, S.A.S. Nagar, Mohali, Punjab *Corresponding Author

Dr. Anju Parihar Consultant, Deptt. Of Critical Care, Grecian Super Speciality Hospital, Sector -69, S.A.S. Nagar, Mohali, Punjab

Dr. Puneet Sharma HOD & Associate Director, Deptt. Of Anaesthesia And Surgical Intensive, Care Unit, Max Super Speciality Hospital, Shalimar Bagh, New Delhi

Dr. Shaveta Dhiman Consultant, Microbiologist, Grecian Super Speciality Hospital, Sector -69, S.A.S. Nagar, Mohali, Punjab

ABSTRACT

Stenotrophomonas maltophilia is an emerging multidrug-resistant global opportunistic pathogen. The increasing incidence of nosocomial and community-acquired S. maltophilia infections is of particular concern for immunocompromised individuals, as this bacterial pathogen is associated with a significant fatality/case ratio. S. maltophilia is an environmental bacterium found in aqueous habitats, including plant rhizospheres, animals, foods, and water sources. Infections of S. maltophilia can occur in a range of organs and tissues; the organism is commonly found in respiratory tract infections. This review summarizes the current literature and presents S. maltophilia as an organism with various molecular mechanisms used for colonization and infection. S. maltophilia can be recovered from polymicrobial infections, most notably from the respiratory tract of cystic fibrosis patients, as a cocolonizer with Pseudomonas aeruginosa. Recent evidence of cell-cell communication between these pathogens has implications for the development of novel pharmacological therapies. Animal models of S. maltophilia infection have provided useful information about the type of host immune response induced by this opportunistic pathogen. Current and emerging treatments for patients infected with S. maltophilia are discussed.

KEYWORDS

INTRODUCTION

Stenotrophomonas maltophilia is a gram-negative, non-fermentative bacillus that has emerged as an important opportunistic pathogen, particularly in immunocompromised patients and those with chronic underlying conditions. Originally classified within the genus Pseudomonas, S. maltophilia was reclassified in 1993 due to its distinct biochemical and genetic characteristics. It is commonly found in various environmental sources, including soil, water, and plants, which contributes to its ubiquitous nature and potential for nosocomial infections. This article delves into the microbiological classification, causes of infection, pathophysiology, early detection methods, treatment options, complications, and ICU care management associated with S. maltophilia.

Microbiological Classification

- **Domain:** Bacteria
- **Phylum:** Proteobacteria
- **Class:** Gammaproteobacteria

- **Order:** Xanthomonadales
- **Family:** Xanthomonadaceae
- **Genus:** Stenotrophomonas
- **Species:** Stenotrophomonas maltophilia

S. maltophilia is characterized as a motile, rod-shaped bacterium that exhibits a distinctive yellow-green pigmentation on culture media. It is oxidase-negative and catalase-positive, with the ability to utilize a wide range of carbon sources.



Causes of Infection

Antimicrobial Resistance

One of the most concerning aspects of S. maltophilia is its intrinsic resistance to many common antibiotics, including penicillins and cephalosporins. This resistance is primarily due to the presence of efflux pumps and beta-lactamases, particularly L1 and L2 beta-lactamases, which contribute to its survival in hostile environments, including hospital settings.

Risk Factors

S. maltophilia infections are more prevalent in certain populations:

1. **Immunocompromised Individuals:** Patients undergoing chemotherapy, organ transplantation, or those with HIV/AIDS are at increased risk.
2. **Chronic Lung Disease:** Conditions such as cystic fibrosis or chronic obstructive pulmonary disease (COPD) can predispose individuals to S. maltophilia colonization and infection.
3. **Prolonged Hospitalization:** Patients in intensive care units (ICUs) or those requiring mechanical ventilation are particularly vulnerable.

High-resolution scanning electron microscopy. (A) Adherence of SMDP92 cells to HEp-2 cells. In addition to the association of bacteria with eukaryotic cells, many bacteria adhere to the glass substratum. Bar, 10 µm. (B) High-magnification image of adhering SMDP92 cells with lateral fimbriae protruding from the bacteria (arrows). Bar, 1 µm. (C) SMDP92 cells adhering to the glass surface (biofilm formation) without epithelial cells. Bar, 10 µm. (D) High-resolution image of biofilm-forming bacteria showing peritrichous fibers attaching to bacteria.

4. **Indwelling Devices:** Catheters and other medical devices can serve as entry points for infection.

Transmission

S. maltophilia is primarily acquired through environmental exposure rather than person-to-person transmission. It can be isolated from various sources, including:

Hospital Water Supplies: Contaminated water systems can facilitate the spread of the bacterium.

Inhalation of Aerosols: Patients on nebulized treatments may inhale aerosolized S. maltophilia from contaminated solutions.

Contaminated Medical Equipment: Improperly sterilized equipment can serve as a vector for infection.

Pathophysiology

S. maltophilia can cause a range of infections, including pneumonia, bloodstream infections, skin and soft tissue infections, and urinary tract infections. The pathophysiological mechanisms by which S. maltophilia causes disease involve several factors:

1. **Adhesion and Biofilm Formation:** The ability of S. maltophilia to adhere to surfaces and form biofilms on medical devices enhances its virulence and resistance to host immune responses.
2. **Immune Evasion:** The bacterium can evade phagocytosis by immune cells through its biofilm matrix and by producing virulence factors that inhibit immune function.



Frontiers -Stenotrophomonas maltophila virulence

3. **Cytotoxicity:** S. maltophilia produces various toxins that can damage host tissues and contribute to inflammation and tissue destruction.

Clinical Presentation

The clinical presentation of S. maltophilia infections varies depending on the site of infection but may include:

Pneumonia: Symptoms include cough, fever, dyspnea, and purulent sputum.

Bacteremia: Fever, chills, and hypotension are common signs.

Urinary Tract Infections: Symptoms may include dysuria, frequency, urgency, and flank pain.

Skin Infections: May present as cellulitis or abscesses.

Pulmonary Abscesses: Localized collections of pus in the lungs may develop in severe cases of pneumonia.

Chronic Lung Disease Exacerbations: In patients with pre-existing lung conditions, S. maltophilia infections can lead to significant exacerbations and decline in respiratory function.



Fig 1 - Virulence factors

ICU Management of Patients Infected with Stenotrophomonas maltophilia

Diagnostic Methods

Early detection of S. maltophilia infections is crucial for effective management. Common diagnostic methods include:

1. **Microbiological Culture:** Isolation of S. maltophilia from clinical specimens (e.g., blood, sputum) is the gold standard for diagnosis.



Various niches in environment and clinical settings as reservoir for S. maltophilia and unique attributes.

2. **Molecular Techniques**: Polymerase chain reaction (PCR) assays can provide rapid identification of S. maltophilia from clinical samples.

3. **Antimicrobial Susceptibility Testing:** Identifying resistance patterns is essential for guiding appropriate therapy.

Treatment

Antimicrobial Therapy

Treatment of S. maltophilia infections can be challenging due to its intrinsic resistance to many antibiotics. However, several options are available:

1. **Trimethoprim-Sulfamethoxazole (TMP-SMX):** This combination antibiotic is considered the first-line treatment for S. maltophilia infections due to its efficacy and lower resistance rates.

2. **Alternative Agents:**

Levofloxacin: May be used as an alternative in cases of TMP-SMX allergy or intolerance.

Minocycline: Has shown efficacy against S. maltophilia but should be used cautiously.

Ceftazidime-avibactam: In certain resistant cases, this combination may be considered.

3. **Combination Therapy:** In severe cases or when there is concern for resistance, combination therapy may be warranted but should be guided by susceptibility testing.

4. **Duration of Therapy:** The duration of antibiotic therapy typically ranges from 7 to 14 days depending on the site and severity of infection.

Supportive Care

In addition to targeted antibiotic therapy, supportive care plays a vital role in managing patients with S. maltophilia infections in the ICU:

1. **Monitoring:** Regular monitoring of vital signs, laboratory parameters (including renal function), and response to therapy is essential.

2. **Fluid Resuscitation:** In cases of septic shock or significant fluid loss, aggressive fluid resuscitation may be necessary.

3. **Nutritional Support:** Early enteral nutrition should be considered to maintain gut integrity and support recovery.

4. **Respiratory Support:** Providing supplemental oxygen or mechanical ventilation for patients with pneumonia or respiratory

failure.

When to suspect S.trophomonas in ICU

Stenotrophomonas maltophilia is an emerging opportunistic pathogen, particularly in ICU settings, characterized by several unique clinical features. This organism is often associated with nosocomial infections, primarily affecting patients with compromised immune systems, such as those with chronic lung diseases, malignancies, or receiving immunosuppressive therapy. One distinctive clinical feature is its propensity to cause respiratory infections, including pneumonia, especially in mechanically ventilated patients. Stenotrophomonas can also lead to bloodstream infections, urinary tract infections, and skin and soft tissue infections. It is notable for its ability to form biofilms on medical devices, contributing to persistent infections. Resistance to multiple antibiotics, including cephalosporins and aminoglycosides, poses significant treatment challenges. However, it is typically susceptible to trimethoprim-sulfamethoxazole (TMP-SMX) and may respond to certain fluoroquinolones and minocycline. In critically ill patients, rapid identification through culture and sensitivity testing is essential for effective management. Clinicians should maintain a high index of suspicion for Stenotrophomonas maltophilia in patients exhibiting atypical infection patterns or those with a history of prolonged antibiotic use or invasive procedures. Early intervention can significantly impact patient outcomes in this vulnerable population.

CONCLUSION

Stenotrophomonas maltophilia is a significant opportunistic pathogen that poses challenges in clinical management due to its intrinsic resistance to many antibiotics and its association with severe infections in vulnerable populations. Early detection, appropriate antimicrobial therapy, and comprehensive ICU care management are essential for improving patient results and minimizing complications associated with this opportunistic pathogen. Continued research into novel treatment options and infection control strategies will be crucial in addressing the growing threat posed by S. maltophilia in healthcare settings.

REFERENCES:

1. Aaron SD, et al. 2005. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 366:463–471 [DOI] [PubMed] [Google Scholar]
2. Adjidé CC, et al. 2010. Stenotrophomonas maltophilia and Pseudomonas aeruginosa water associated microbiologic risk assessment in Amiens' University Centre. Pathol. Biol. (Paris) 58:e1–e15 doi: 10.1016/j.patbio.2009.07.006 [DOI] [PubMed] [Google Scholar]
3. Adjidé CC, et al. 2010. A sensitive, specific and predictive isolation medium developed for Stenotrophomonas maltophilia study in healthcare settings. Pathol. Biol. (Paris) 58:11–17 [DOI] [PubMed] [Google Scholar]
4. Akçakaya AA, et al. 2011. A cluster of acute-onset postoperative endophthalmitis over a 1-month period: investigation of an outbreak caused by uncommon species. Br. J. Ophthalmol. 95:481–484 [DOI] [PubMed] [Google Scholar]
5. Akova M, Bonfiglio G, Livermore DM. 1991. Susceptibility to β-lactam antibiotics of mutant strains of Xanthomonas maltophilia with high- and low-level constitutive expression of L1 and L2 β-lactamases. J. Med. Microbiol. 35:208–213 [DOI] [PubMed] [Google Scholar]
6. Al-Hamad A, Upton M, Burnie J. 2009. Molecular cloning and characterization of SmrA, a novel ABC multidrug efflux pump from Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 64:731–734 [DOI] [PubMed] [Google Scholar]
7. Al-Jasser AM. 2006. Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem. Ann. Clin. Microbiol. Antimicrob. 5:23–25 doi:10.1186/1476-0711-5-23 [DOI] [PMC free article] [PubMed] [Google Scholar]
8. Al Johani SM, et al. 2010. Prevalence of antimicrobial resistance among gram-negative isolates in an adult intensive care unit at a tertiary care center in Saudi Arabia. Ann. Saudi Med. 30:364–369 [DOI] [PMC free article] [PubMed] [Google Scholar]
9. Al Naiemi N, Duim B, Bart A. 2006. A CTX-M extended-spectrum β-lactamase in Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J. Med. Microbiol. 55:1607–1608 [DOI] [PubMed] [Google Scholar]
10. Alonso A, Martínez JL. 1997. Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 41:1140–1142 [DOI] [PMC free article] [PubMed] [Google Scholar]
11. Alonso A, Martínez JL. 2000. Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 44:3079–3086 [DOI] [PMC free article] [PubMed] [Google Scholar]
12. Alonso A, Sanchez P, Martínez JL. 2000. Stenotrophomonas maltophilia D457R contains a cluster of genes from gram-positive bacteria involved in antibiotic and heavy metal resistance. Antimicrob. Agents Chemother. 44:1778–1782 [DOI] [PMC free article] [PubMed] [Google Scholar]
13. Apisarnthanarak A, et al. 2003. Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case-control study. Infect. Control Hosp. Epidemiol. 24:269–274 [DOI] [PubMed] [Google Scholar]
14. Araoka H, Baba M, Yoneyama A. 2010. Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996–2009. Eur. J. Clin. Microbiol. Infect. Dis. 29:605–608 [DOI] [PubMed] [Google Scholar]
15. Arvanitidou M, Vayona A, Spanakis N, Tsakris A. 2003. Occurrence and antimicrobial resistance of Gram-negative bacteria isolated in haemodialysis water and dialysate of renal units: results of a Greek multicentre study. J. Appl. Microbiol. 95:180–185 [DOI] [PubMed] [Google Scholar]
16. Avison MB, et al. 2002. Differential regulation of L1 and L2 β-lactamase expression in Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 49:387–389 [DOI] [PubMed] [Google Scholar]
17. Avison MB, Higgins CS, von Heldreich CJ, Bennett PM, Walsh TR. 2001. Plasmid location and molecular heterogeneity of the L1 and L2 β-lactamase genes of Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 45:413–419 [DOI] [PMC free article] [PubMed] [Google Scholar]
18. Avison MB, von Heldreich CJ, Higgins CS, Bennett PM, Walsh TR. 2000. A TEM-2 β-lactamase encoded on an active Tn1-like transposon in the genome of a clinical isolate of Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 46:879–884 [DOI] [PubMed] [Google Scholar]
19. Aydin K, Kőksal I, Kaygusuz S, Kaklikkaya I, Caylan R, Özdemir R. 2000. Endocarditis caused by Stenotrophomonas maltophilia. Scand. J. Infect. Dis. 32:427–430 [DOI] [PubMed] [Google Scholar]
20. Ba BB, Feghali H, Arpin C, Saux M- C, Quentin C. 2004. Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. Antimicrob. Agents Chemother. 48:946–953 [DOI] [PMC free article] [PubMed] [Google Scholar]
21. Babálová M, Blahová J, Lešická-Hupková M, Krcméry V, Kubonová K. 1995. Transfer of ceftazidime and aztreonam resistance from nosocomial strains of Xanthomonas (Stenotrophomonas) maltophilia to a recipient strain of Pseudomonas aeruginosa ML-1008. Eur. J. Clin. Microbiol. Infect. Dis. 14:925–927 [DOI] [PubMed] [Google Scholar]
22. Bajaj N, Sheth AN, Burgess JJ, Husain H, Brooke JS. 2009. Disinfectant reduction of biofilm formation of Stenotrophomonas maltophilia, abstr AE4. Abstr. 59th Annu. Conf. Can. Soc. Microbiol. Canadian Society of Microbiologists, Ottawa, Ontario, Canada [Google Scholar]
23. Ballmann M, von der Hardt H. 2002. Hypertonic saline and recombinant human DNase: a randomized crossover pilot study in patients with cystic fibrosis. J. Cyst. Fibros. 1:35–37 [DOI] [PubMed] [Google Scholar]
24. Banerjee R, Roy D. 2009. Codon usage and gene expression pattern of Stenotrophomonas maltophilia R551-3 for pathogenic mode of living. Biochem. Biophys. Res. Commun. 390:177–181 [DOI] [PubMed] [Google Scholar]
25. Barbeau J, ten Bokum L, Gauthier C, Prévost AP. 1998. Cross-contamination potential of salvia ejectors used in dentistry. J. Hosp. Infect. 40:303–311 [DOI] [PubMed] [Google Scholar]
26. Barbier-Frebourg N, Boutiba-Boubaker I, Nouvellon M, Lemeland J-F. 2000. Molecular investigation of Stenotrophomonas maltophilia isolates exhibiting rapid emergence of ticarcillin-clavulanate resistance. J. Hosp. Infect. 45:35–41 [DOI] [PubMed] [Google Scholar]
27. Barbolla R, et al. 2004. Class 1 integrons increase trimethoprim-sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates. Antimicrob. Agents Chemother. 48:666–669 [DOI] [PMC free article] [PubMed] [Google Scholar]
28. Bathe S, Lebuhn M, Ellwart JW, Wuertz S, Hausner M. 2004. High phylogenetic diversity of transconjugants carrying plasmid pJP4 in an activated sludge-derived microbial community. FEMS Microbiol. Lett. 235:215–219 [DOI] [PubMed] [Google Scholar]
29. Berg G. 2009. Plant-microbe interactions promoting plant growth and health: perspectives for controlled use of microorganisms in agriculture. Appl. Microbiol. Biotechnol. 84:11–18 [DOI] [PubMed] [Google Scholar]
30. Berg G, Eberl L, Hartmann A. 2005. The rhizosphere as a reservoir for opportunistic human pathogenic bacteria. Environ. Microbiol. 7:1673–1685 [DOI] [PubMed] [Google Scholar]
31. Berg G, Roskot N, Smalla K. 1999. Genotypic and phenotypic relationships between clinical and environmental isolates of Stenotrophomonas maltophilia. J. Clin. Microbiol. 37:3594–3600 [DOI] [PMC free article] [PubMed] [Google Scholar]
32. Berney M, Hammes F, Bosshard F, Weilenmann H-U, Egli T. 2007. Assessment and interpretation of bacterial viability by using the LIVE/DEAD BacLight kit in combination with flow cytometry. Appl. Environ. Microbiol. 73:3283–3290 [DOI] [PMC free article] [PubMed] [Google Scholar]
33. Bin Abdulhak AA, Zimmerman V, Al Beirouti BT, Baddour LM, Tleyjeh IM. 2009. Stenotrophomonas maltophilia infectious of intact skin: a systematic review of the literature. Diagn. Microbiol. Infect. Dis. 63:330–333 [DOI] [PubMed] [Google Scholar]
34. Blahová J, Králiková K, Krcméry V, Sr, Chmelarová E, Toršová V. 1998. Two nosocomial strains of Stenotrophomonas maltophilia transferring antibiotic resistance to Proteus mirabilis P-38 recipient strain. J. Chemother. 10:22–24 [DOI] [PubMed] [Google Scholar]
35. Blondel-Hill E, Henry DA, Speert DP. 2007. Pseudomonas, p 734–748 In Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA. (ed), Manual of clinical microbiology, 9th ed, vol 1 ASM Press, Washington, DC: [Google Scholar]